

**VI. Segment Information \***

(Billions of Yen)

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease
<b>Net Sales</b>	<b>1,538.3</b>	<b>1,466.0</b>	<b>1,419.4</b>	<b>1,508.9</b>	<b>702.5</b>	<b>786.9</b>	<b>84.4</b>	<b>12.0%</b>
Pharmaceuticals	1,448.5							
Ethical drugs	1,384.1	1,317.7	1,267.4	1,358.8	627.0	710.4	83.4	13.3%
Japan	549.0	548.9	578.5	592.2	296.0	296.3	0.2	0.1%
Overseas	835.1	768.9	689.0	766.6	331.0	414.1	83.1	25.1%
Consumer healthcare	64.4	58.2	60.3	61.7	31.8	33.6	1.8	5.6%
Others	89.9							
Others		94.8	96.3	93.1	46.0	45.2	-0.8	-1.6%
Adjustments		-4.8	-4.6	-4.6	-2.3	-2.3	0.1	
<b>Operating Income</b>	<b>306.5</b>	<b>420.2</b>	<b>367.1</b>	<b>265.0</b>	<b>211.0</b>	<b>108.6</b>	<b>-102.5</b>	<b>-48.6%</b>
Pharmaceuticals	296.9							
Ethical drugs		400.6	346.0	243.8	198.4	95.3	-103.0	-51.9%
Consumer healthcare		11.0	12.2	11.8	7.5	8.4	1.0	13.4%
Others	9.5							
Others		10.8	11.0	11.7	6.3	5.8	-0.5	-8.3%
Adjustments		-2.2	-2.2	-2.2	-1.1	-1.0	0.1	

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease
<b>Capital expenditures</b>	<b>906.9</b>	<b>114.5</b>	<b>148.9</b>	<b>1,255.2</b>	<b>1,111.6</b>	<b>197.9</b>	<b>-913.7</b>	<b>-82.2%</b>
Pharmaceuticals	** 898.7							
Ethical drugs		110.6	144.7	*** 1,249.1	*** 1,109.2	**** 195.1	-914.1	-82.4%
Consumer healthcare		0.5	0.4	0.7	0.6	0.4	-0.1	-24.5%
Others	8.2							
Others		3.4	3.7	5.4	1.9	2.4	0.5	24.2%
Adjustments		-	-	-	-	-	-	

\*\* Including both "increase of intangible assets and goodwill due to acquisition of Millennium" and "increase of intangible assets due to division and restructuring of TAP into wholly owned subsidiary"

\*\*\* Including increase of intangible assets and goodwill due to acquisition of Nycomed.

\*\*\*\* Including increase of intangible assets and goodwill due to acquisition of URL Pharma and Multilab.

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease
<b>Depreciation</b>	<b>118.1</b>	<b>98.7</b>	<b>91.5</b>	<b>126.9</b>	<b>49.3</b>	<b>79.7</b>	<b>30.5</b>	<b>61.8%</b>
Pharmaceuticals	110.1							
Ethical drugs		93.0	86.1	121.7	46.8	77.1	30.3	64.8%
Consumer healthcare		0.8	0.8	0.8	0.4	0.4	0.0	2.2%
Others	7.2							
Others		5.6	5.2	4.9	2.4	2.5	0.1	5.4%
Adjustments		-0.7	-0.6	-0.6	-0.3	-0.3	-0.0	

	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease
<b>Amortization of goodwill</b>		<b>15.1</b>	<b>14.1</b>	<b>22.2</b>	<b>6.6</b>	<b>16.1</b>	<b>9.5</b>	<b>143.3%</b>
Pharmaceuticals								
Ethical drugs		14.6	13.7	22.1	6.5	16.1	9.6	147.6%
Consumer healthcare		-	-	-	-	-	-	
Others								
Others		0.5	0.5	0.1	0.1	0.0	-0.1	-98.3%
Adjustments		-	-	-	-	-	-	

\* Effective from the FY2010, the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information has been adopted. The figures for "FY09" are calculated and indicated after applying said accounting standard.